The cardiologist and smoking cessation

Current Opinion in Cardiology

Volumn 25, Issue 5, 2010, Pages 469-477

  Aboyans, Victor ^a   Thomas, Daniel ^b   Lacroix, Philippe ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

cardiovascular; counseling; prevention; smoking; tobacco

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NORTRIPTYLINE; PLACEBO; STATIN; VARENICLINE;

ABDOMINAL AORTA ANEURYSM; ACUPUNCTURE; CARDIOLOGIST; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG MECHANISM; FIBRINOLYTIC THERAPY; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; INSOMNIA; NAUSEA; NICOTINE REPLACEMENT THERAPY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SEIZURE; SKIN IRRITATION; SLEEP DISORDER; SMOKING CESSATION; STROKE; TOBACCO DEPENDENCE; TOOTH DISEASE; XEROSTOMIA; CARDIOLOGY; CARDIOVASCULAR DISEASES; PHYSICIAN ATTITUDE;

CARDIOLOGY; CARDIOVASCULAR DISEASES; HUMANS; PHYSICIAN'S ROLE; SMOKING CESSATION;

EID: 77955468991     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32833cd4f7     Document Type: Review

References (61)

1. The World Health Report 2003: Shaping the future. World Health Organization; 2003. www.who.int/whr/2003.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3:e442.
3. Pearl R. Tobacco smoking and longevity. Science 1938; 87:216-217.
4. Yusuf S, Hawken S, Ôunpuu S, et al. Effect of modifiable risk factors associated with myocardial infarction in 52 countries (the INTER-HEART study): Case-control study. Lancet 2004; 364:937-952.
5. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Circulation 2008; 118: 576-585.
6. Quist-Paulsen P, Lydersen S, Bakke PS, Gallefoss F. Cost-effectiveness of a smoking cessation program in patients admitted for coronary heart disease. Eur J Cardiovasc Prev Rehabil 2006; 13:274-280.
7. Kotseva K, Wood D, De Backer G, et al., for the EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: A comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373:929-940. This paper shows the improvement in the management of several risk factors, 6 months after an AMI, but also highlights a poor and steady rate of smoking cessation in several European countries between 1995 and 2005.
8. Ezzati M, Henley SJ, Thun MJ, Lopez AD. Role of smoking in global and regional cardiovascular mortality. Circulation 2005; 112:489-497.
9. Mähönen MS, McElduff P, Dobson AJ, et al. Current smoking and the risk of nonfatal myocardial infarction in the WHO MONICA Project populations. Tob Control 2004; 13:244-250.
10. Marques-Vidal P, Cambou JP, Ferrières J, et al. Distribution and treatment of cardiovascular risk factors in coronary patients: The PREVENIR study [in French]. Arch Mal Coeur Vaiss 2001; 94:673-680.
11. Teo KK, Ounpuu S, Hawken S, on behalf of the INTERHEART study investigators. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: A case-control study. Lancet 2006; 368:647-658.
12. Schane RE, Ling PM, Glantz SA. Health effects of light and intermittent smoking: A review. Circulation 2010; 121:1518-1522. This thorough review tackles the wrong idea that light or intermittent smoking is not harmful.
13. Funabashi N, Asano M, Komuro I. Predictors of noncalcified plaques in the coronary arteries of 242 subjects using multislice computed tomography and logistic regression models. Int J Cardiol 2007; 117:191-197.
14. Budoff MJ, McClelland RL, Nasir K, et al. Cardiovascular events with absent or minimal coronary calcification: The Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J 2009; 158:554-561.
15. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989; 298:789-794.
16. Aboyans V, Criqui MH. The epidemiology of peripheral arterial disease. In: Robert Dieter, editor. Peripheral arterial disease. McGraw Hill; 2009. pp. 1-25.
17. Fowkes FG. Epidemiology of atherosclerotic arterial disease in the lower limbs. Eur J Vasc Surg 1988; 2:283-291.
18. Aboyans V, Criqui MH, Denenberg JO, et al. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 2006; 113:2623-2629.
19. Lederle FA, Johnson GR, Wilson SE, et al. The aneurysm detection and management study screening program: Validation cohort and final results. Arch Intern Med 2000; 160:1425-1430.
20. MacSweeney STR, Powell JT, Greenhalgh RM. Pathogenesis of abdominal aortic aneurysm. Br J Surg 1994; 7:935-941.
21. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: Nearly as large as smoking. Circulation 2005; 111:2684-2698.
22. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease. J Am Coll Cardiol 2004; 43:1731-1737.
23. Unal B, Critchley JA, Capewell S. Modeling the decline in coronary heart disease deaths in England and Wales, 1981-2000. BMJ 2005; 331:614.
24. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2003:CD003041. DOI: 10.1002/14651858.CD003041.pub2
25. Peters RW, Brooks MM, Todd L, et al. Smoking cessation and arrhythmic death: The CAST experience. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. J Am Coll Cardiol 1995; 26:1287-1292.
26. Chow CK, Jolly S, Rao-Melacini P, et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010; 121:750-758. In this contemporary study in 41 countries, the current benefits of smoking cessation are highlighted, despite the use of up-to-date therapies to improve survival after an acute coronary syndrome.
27. Crabtree TD, Codd JE, Fraser VJ, et al. Multivariate analysis of risk factors for deep and superficial sternal infection after coronary artery bypass grafting at a tertiary care medical center. Semin Thorac Cardiovasc Surg 2004; 16:53-61.
28. Ngaage DL, Martins E,Orkell E, et al. The impact of the duration of mechanical ventilation on the respiratory outcome in smokers undergoing cardiac surgery. Cardiovasc Surg 2002; 10:345-350.
29. van Domburg RT, Meeter K, van Berkel DF, et al. Smoking cessation reduces mortality after coronary artery bypass surgery: A 20-year follow-up study. J Am Coll Cardiol 2000; 36:878-883.
30. Hasdai D, Garratt KN,Grill DE, et al. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med 1997; 336:755-761.
31. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: Scientific review. JAMA 2002; 288:1388-1395.
32. Hooi JD, Stoffers HE, Knottnerus JA, van Ree JW. The prognosis of noncritical limb ischemia: A systematic review of population-based evidence. Br J Gen Pract 1999; 49:49-55.
33. Jonason T, Ringqvist I. Factors of prognostic importance for subsequent rest pain in patients with intermittent claudication. Acta Medica Scand 1985; 218:27-33.
34. Juergens JE, Parker NW, Hines EA. Arteriosclerosis obliterans: Review of 520 cases with special reference to pathogenic and prognostic factors. Circulation 1960; 21:188-195.
35. Willigendael EM, Teijink JA, Bartelink ML, et al. Smoking and the patency of lower extremity bypass grafts: A meta-analysis. J Vasc Surg 2005; 42:67-74.
36. Brown LC, Powell JT. Risk factors for aneurysm rupture in patients kept under ultrasound surveillance: UK Small Aneurysm Trial Participants. Ann Surg 1999; 230:289-296.
37. Rigotti NA, Munafo MR, Stead LF. Smoking cessation interventions for hospitalized smokers: A systematic review. Arch Intern Med 2008; 168: 1950-1960.
38. McHugh F, Lindsay GM, Hanlon P, et al. Nurse led shared care for patients on the waiting list for coronary artery bypass surgery: A randomised controlled trial. Heart 2001; 86:317-323.
39. van Spall HGC, Chong A, Tu JV. Inpatient smoking-cessation counseling and all-cause mortality in patients with acute myocardial infarction. Am Heart J 2007; 154:213-220.
40. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services. Public Health Service. May 2008.
41. Bovet P, Perret F, Cornuz J, et al. Improved smoking cessation in smokers given ultrasound photographs of their own atherosclerotic plaques. Prev Med 2002; 34:215-220.
42. Rodondi N, Bovet P, Hayoz D, Cornuz J. The Impact of CAROtid plaque Screening on Smoking (CAROSS) cessation and control of other cardiovascular risk factors: Rationale and design of a randomized controlled trial. Contemp Clin Trials 2008; 29:767-773.
43. Centers for Disease Control and Prevention. Cigarette smoking among Adults: United States, 2000. MMWR Morb Mortal Wkly Rep 2002; 51:642-645.
44. Aboyans V, Pinet P, Lacroix P, Laskar M. Knowledge and management of smoking-cessation strategies among cardiologists in France: A nationwide survey. Arch Cardiovasc Dis 2009; 102:193-199. A detailed questionnaire was randomly sent to French cardiologists in order to assess their level of knowledge and involvement in smoking-cessation strategies.
45. Terrier JF, Thomas D, Belougne D, Freour P. Attitudes and opinions of French cardiologists towards smoking. Eur J Epidemiol 1995; 11:615-620.
46. Abuissa H, Lavie C, Spertus J, O'Keefe J. Personal health habits of American cardiologists. Am J Cardiol 2006; 97:1093-1096.
47. Kotz D, Wagena EJ, Wesseling G. Smoking cessation practices of Dutch general practitioners, cardiologists, and lung physicians. Respir Med 2007; 101:568-573.
48. Pipe A, Sorensen M, Reid R. Physician smoking status, attitudes toward smoking, and cessation advice to patients: An international survey. Patient Educ Couns 2009; 74:118-123.
49. Hatsukami DK, Stead LF, Gupta PC. Tobacco addiction. Lancet 2008; 371:2027-2038. A thorough review of tobacco addiction, including the underlying neurobiology and behavioral processes. This seminar is of major interest to better understand how the current methods improve smoking cessation rates, and why major progress is still expected.
50. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008. CD000146. DOI: 10.1002/ 14651858.CD000146.pub3.
51. Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf 1998; 18:297-308.
52. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996; 335:1792-1798.
53. Paciullo CA, Short MR, Steinke DT, Jennings HR. Impact of nicotine replacement therapy on postoperative mortality following coronary artery bypass graft surgery. Ann Pharmacother 2009; 43:1197-1202.
54. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustainedrelease bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340:685-691.
55. Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: A multicentre, randomised study. Eur Heart J 2003; 24:946-955.
56. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007. CD006103. DOI: 10.1002/ 14651858.CD006103.pub2.
57. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustainedrelease bupropion for smoking cessation: A randomized controlled trial. JAMA 2006; 296:56-63.
58. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised open label trial. Thorax 2008; 63:717-724.
59. Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: A randomized trial. Circulation 2010; 121:221-229. This recent randomized trial assessed the efficacy and safety of varenicline for smoking cessation in patients with cardiovascular diseases.
60. Barth J, Critchley J, Bengel J. Psychosocial interventions for smoking cessation in patients with coronary heart disease. Cochrane Database Syst Rev 2008. CD006886. DOI: 10.1002/14651858.CD006886.
61. Jabbour S, Reddy KS, Muna WFT, Achutti A. Cardiovascular disease and the global tobacco epidemic: A wake-up call for cardiologists. Int J Cardiol 2002; 86:185-192.